Butterfly Skin Therapy Pipeline Primed For Transformation

The odds of having an approved therapy for epidermolysis bullosa (EB) by the end of 2021 have improved with the news that US regulators have fast-tracked Amryt Pharma's Oleogel-S10 but gene therapies are also coming through the pipeline that could tackle the underlying cause of the rare genetic disorder that causes skin to be extremely fragile.

First up, Ireland's Amryt, which is listed on the NASDAQ and London's AIM market, has revealed that the US Food and Drug Administration has granted a priority review of its new drug application for Oleogel-S10 (to be marketed as Filsuvez) for cutaneous manifestations of junctional and dystrophic EB, which is also called butterfly skin as the patient’s skin becomes as fragile as that insect’s wings